Co-Diagnostics Execs Join Utah Trade Mission to Expand European Diagnostics Ties

Event summary

  • Co-Diagnostics executives will participate in a trade mission to Switzerland and Germany from April 13-22, 2026, alongside Utah Governor Cox and WTC Utah.
  • The mission includes visits to Roche Diagnostics, UBS, and Zurich Innovation Park, among other key industry leaders.
  • Executives will also attend the ESCMID Global 2026 Congress in Munich to meet prospective customers and distributors.
  • The trade mission aligns with Co-Dx's preparations for a 510(k) submission for its real-time PCR point-of-care diagnostic platform.
  • This follows recent international joint ventures in India and Saudi Arabia.

The big picture

Co-Diagnostics is deepening its European footprint at a time when decentralized diagnostics platforms are gaining traction. The trade mission comes as the company prepares for a critical FDA submission, positioning it to compete with established players like Roche. Success in these efforts could validate its strategy of combining regulatory approvals with global partnerships.

What we're watching

Regulatory Progress
The pace at which Co-Dx secures FDA 510(k) clearance for its PCR platform will determine its market entry timing.
Partnership Expansion
Whether the trade mission yields concrete deals with European diagnostics leaders like Roche.
Global Strategy
How Co-Dx balances its international joint ventures with its core U.S. regulatory priorities.